Trillium
Therapeutics (NASDAQ:TRIL) climbed 1,330% last year, but unlike most of its soaring biotech stock peers, its business has nothing to do with fighting the SARS-CoV-2 coronavirus. It s an oncology specialist. And another banner year for investors could be coming in 2021 as the company gets more data from its cancer-fighting candidates and works toward a long-term goal of replacing a common method to treat the disease.
Image source: Getty Images
In a league of its own
Human cells have a certain protein on their surface that signals to the immune system not to attack them. Nearly all cancers boost this protein, called CD47, to protect themselves and avoid detection. In March,
The Globe and Mail Brian Donovan Published December 14, 2020
Valuations for Canadian biotech stocks trading on the Toronto Stock Exchange and TSX Venture Exchange.
The screen
We used StockCalc’s screener to select the 10 largest biotechs listed on the TSX and Venture Exchange. We then used StockCalc’s valuation tools to calculate fundamental (or intrinsic) valuation for each stock to see whether it is undervalued or overvalued compared with its price.
Overview of the techniques used:
Story continues below advertisement
Discounted cash flow (DCF value) is a valuation technique where cash flow projections are discounted back to the present to calculate value per share;
Forget Shopify (TSX:SHOP): This Tiny TSX Stock Has Returned 1,900% in 2020 fool.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.ca Daily Mail and Mail on Sunday newspapers.
Cancer Monoclonal Antibodies Global Market Report 2020-30: COVID-19 Growth and Change - Press Release digitaljournal.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from digitaljournal.com Daily Mail and Mail on Sunday newspapers.